Feedback

Novavax shows 96-percent efficacy against basic strain of Covid-19

Source : 112 Ukraine

It also proves to be quite efficient against the British strain of the disease
10:17, 12 March 2021

Open source

The U.S.-made Novavax vaccine shows 96.4-percent efficiency against the basic strain of Covid-19. According to Reuters, it also shows 86.3-percent efficacy against the British strain.

Phase three of the tests of NVX CoV2373 vaccine took place in Great Britain. The research involved more than 15,000 participants aged fgrom 18 to 84. 27 percent of these people were over 65. 

The company claimed that the drug proved to be 100%-effective in tough cases. 

"In a smaller trial conducted in South Africa - where volunteers were primarily exposed to another newer, more contagious variant widely circulating there and spreading around the world - the Novavax vaccine was 55% effective, based on people without HIV, but still fully prevented severe illness", reads the story.

Related: Novavax company claims readiness of new Covid-19 vaccine

Novavax plans to develop their vaccine on eight production playgrounds, including the Indian Institute of Serum.

Earlier, Ukraine successfully completed the negotiations on the increase of supplies of Novavax. The government managed to make a deal on the supply of another 5,000,000 doses; the general amount is supposed to make 15,000,000 doses.

Related: Ukraine aggress on supply of extra 5 million doses of NovaVax vaccine

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more